In the escape phase, the TME becomes immunosuppressive or “cold,” dominated by Tregs, MDSCs, M2 tumor-associated macrophages (TAMs), and elevated levels of IL-10 and TGF-β, facilitating immune evasion and therapy resistance. The gene discussed is TGFB1; the disease is neoplasm.